首页|HER2低表达和HER2阴性表达乳腺癌患者临床、病理特征及预后

HER2低表达和HER2阴性表达乳腺癌患者临床、病理特征及预后

扫码查看
目的 分析人表皮生长因子受体2(HER2)低表达和HER2阴性表达乳腺癌患者临床、病理特征及预后.方法 行手术切除的非HER2过表达型乳腺癌患者257例中,管腔A型82例,管腔B型118例,三阴性57例.分析非HER2过表达型乳腺癌患者中HER2低表达和HER2阴性表达患者的临床、病理特征及预后.分析管腔A、B型乳腺癌患者和三阴性乳腺癌患者中HER2低表达和HER2阴性表达患者的临床、病理特征及预后.结果 非HER2过表达型乳腺癌患者中,HER2低表达和HER2阴性表达不同年龄、绝经状态、组织学分级、肿瘤浸润淋巴细胞(TILs)百分比、程序性死亡配体1(PD-L1)表达及Ki-67表达的患者比例差异均有统计学意义(P<0.05或P<0.01).管腔A、B型乳腺癌患者中,HER2低表达和HER2阴性表达患者不同年龄、绝经状态、TILs百分比、PD-L1表达及Ki-67表达的患者比例差异亦有统计学意义(P<0.05或P<0.01).三阴性乳腺癌患者中,HER2低表达和HER2阴性表达患者不同组织学分级、TILs百分比、PD-L1表达及Ki-67表达的患者比例差异均有统计学意义(P<0.05或P<0.01).非HER2过表达型乳腺癌和管腔A、B型乳腺癌患者中,HER2低表达和HER2阴性表达患者总生存期(OS)率和无病生存期(DFS)率相仿(P>0.05).三阴性乳腺癌患者中,HER2低表达OS率和DFS率均高于HER2阴性表达(P<0.05).结论 HER2低表达和HER2阴性表达乳腺癌患者具有不同的临床、病理特征及预后,临床应根据不同的HER2状态制定相应的治疗策略.
Clinical and pathological features and prognosis of breast cancer patients with HER2 low expression and HER2 negative expression
Objective To analyze the clinical and pathological features and prognosis of breast cancer patients with human epidermal growth factor receptor 2(HER2)low expression and HER2 negative expression.Methods A total of 257 breast cancer patients without HER2-overexpression underwent surgical resection,of whom 82 cases were with luminal type A breast cancer,118 cases were with luminal type B breast cancer,and 57 cases were with triple-negative type breast cancer.The clinical and pathological features and prognosis of HER2 low expression and HER2 negative expression in the patients with non HER2-overexpression,luminal A and B type breast cancer,and triple-negative type breast cancer were analyzed.Results There were significant differences in the proportion of patients of different age,menopausal status,histological grade,percentage of tumor infiltrating lymphocytes(TILs),expressions of programmed death ligand 1(PD-L1)and Ki-67 between the patients with HER2 low expression and those with HER2 negative expression in breast cancer patients without HER2-overexpression(P<0.05 or P<0.01).There were significant differences in the proportion of patients of different age,menopausal status,TILs percentage,PD-L1 expression and Ki-67 expression between the patients with HER2 low expression and HER2 negative expression in breast cancer patients with luminal A and B type breast cancer(P<0.05 or P<0.01).There were significant differences in the proportion of patients of different histological grade,TILs percentage,PD-L1 expression and Ki-67 expression between the patients with HER2 low expression and those with HER2 negative expression in breast cancer patients with triple-negative type breast cancer(P<0.05 or P<0.01).The rates of overall survival(OS)and disease-free survival(DFS)of the patients with HER2 low expression and those with HER2 negative expression in breast cancer patients without HER2-overexpression,or with luminal A and B type were similar(P>0.05).The rates of OS and DFS of the patients with HER2 low expression were higher than those with HER2 negative expression in breast cancer patients with triple-negative type(P<0.05).Conclusion Breast cancer patients with HER2 low expression and HER2 negative expression have different clinical and pathological features and prognosis,and different clinical treatment strategies should be taken according to different HER2 status.

Human epidermal growth factor receptor 2Breast cancer

李晓芳、黄岳青、王路、刘标、黄敏

展开 >

215006 江苏苏州,南京医科大学附属苏州医院中医科

215006 江苏苏州,南京医科大学附属苏州医院全科医学科

215006 江苏苏州,南京医科大学附属苏州医院病理科

人表皮生长因子受体2 乳腺癌

江苏省医学重点学科苏州市科技发展计划项目苏州市产业技术创新专项苏州市姑苏卫生人才计划项目

ZDXK202252SKJYD2021110SYD2017173GSWS2021037

2024

江苏医药
江苏省人民医院(南京医科大学第一附属医院)

江苏医药

影响因子:0.707
ISSN:0253-3685
年,卷(期):2024.50(2)
  • 25